EverPoint Asset Management’s Travere Therapeutics TVTX Stock Holding History

EverPoint Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$23.9M	Buy	1,260,000 +660,000	+110%	+$13.5M	0.44%	51
2016 Q3	$13.4M	Buy	600,000 +50,000	+9%	+$952K	0.24%	107
2016 Q2	$9.8M	Buy	+550,000	New	+$8.9M	0.19%	149
2015 Q4	–	Sell	-175,000	Closed	-$3.55M	–	531
2015 Q3	$3.55M	Buy	175,000 +60,000	+52%	+$1.78M	0.09%	266
2015 Q2	$3.81M	Buy	+115,000	New	+$3.15M	0.07%	318
2014 Q3	–	Sell	-100,000	Closed	-$1.17M	–	542
2014 Q2	$1.17M	Buy	+100,000	New	+$1.35M	0.02%	447

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EverPoint Asset Management's TVTX Position: Q4 2016 in Review

EverPoint Asset Management increased its Travere Therapeutics (TVTX) stake by 110% in Q4 2016, buying an estimated $13.5M and bringing the position to 1,260,000 shares worth $23.9M. The position accounts for 0.44% of the portfolio, ranked #51.

EverPoint Asset Management first reported a position in TVTX in Q2 2014 and has held it in 6 quarters since. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

EverPoint Asset Management held 1,260,000 shares of Travere Therapeutics worth $23.9M as of Q4 2016.
EverPoint Asset Management bought 660,000 Travere Therapeutics shares in Q4 2016, an estimated $13.5M.
Travere Therapeutics made up 0.44% of EverPoint Asset Management's portfolio in Q4 2016, its #51 holding.
EverPoint Asset Management first reported a position in Travere Therapeutics in Q2 2014 and has held it in 6 quarters since.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.